Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06040827

A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension

The objectives of this prospective observational cohort study are to evaluate the safety, reliability, reproducibility, and accuracy of the Canary canturioTM te post-TKA.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ozark Orthopaedics, Fayetteville, Arkansas, United States

Loading trial locations.

About this study

Group 1 (Test): Zimmer Persona® Personalized Knee System with Canary canturioTM (CTE) tibial extension Group 2 (Control): Zimmer Persona® Personalized Knee System with 14 mm +30 mm stem extension Safety Endpoint The nature, severity, and frequency of safety risks in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.

The safety endpoint is the percentage of patients that meet any of the following criteria within 5 years post-TKA:

  • Revision (tibia only)
  • Aseptic loosening
  • Instability (or unrecognized septic loosening)
  • Intra-operative fracture of bone or device
  • Post-operative fracture of bone or device
  • Radiologic changes including:
  • Lytic lines (radiolucency greater than 2 mm in 2 or more zones)
  • Focal lysis(progressive osteolytic lesion)
  • Osteolysis (3mm in more than 1 zone)
  • Device fracture or failure (tibia only)
  • Cortical thickening or periosteal reactions

Secondary Endpoints

The secondary endpoints (for 5 years post-TKA) are:

Successful Data Collection

  • Percent of days with step-count data transmitted
  • Percent of days with one or more gait bouts triggered and transmitted
  • Percent of days with qualified gait cycles >0 (applicable for walking speed, stride length, tibia ROM, functional knee ROM and cadence)
  • Percent of days with step-count data transmitted and qualified gait cycles >0 (applicable for distance) Pain and Functional Performance
  • Knee Injury and Osteoarthritis Outcome Score (KOOS - JR)
  • Numeric Pain Rating Scale (NPRS)
  • Quality-of-life- EQ-5D-5L

Effectiveness Endpoints (Reliability, Reproducibility, and Accuracy) The reliability, precision and accuracy of walking speed using measurements at 1 year and 2 years post TKA will be assessed with a cohort of 75 patients from Group 1 (with the CTE). Additionally, the reliability, precision and accuracy of all 7 gait parameters (walking speed, cadence, stride length, functional knee ROM, tibia ROM, step count and distance) using measurements at 1 year with 3 different walking speeds, will be assessed with a consecutive cohort of 25 patients from Group 1 in a gait lab.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion

  • Patient must be 18 years of age or older
  • Patient qualifies for primary total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to osteoarthritis, limited to:
  • Mild or Moderate valgus, varus, or flexion deformities
  • Patient must be willing and able to complete the protocol required follow-up
  • Patient is indicated for a 58mm or 30mm tibial stem extension
  • Patient has participated in the study-related informed consent process
  • Patient is willing and able to provide written Informed Consent by signing and dating the IRB approved informed consent
  • Patient has a platform-compatible personal computer located in their dwelling with appropriate wireless internet access and a USB port
  • Independent of study participation, patient is a candidate for commercially available Persona Personalized Knee System implanted in accordance with product labeling

Exclusion

  • Simultaneous bilateral TKA
  • Staged bilateral TKA less than 6 months from indexed procedure
  • Patient is a current alcohol or drug abuser
  • Patient is known to be pregnant, breastfeeding, or considered a member of a protected class (e.g., prisoner, mentally incompetent, etc.)
  • Patient has a psychiatric illness or cognitive deficit that will not allow proper informed consent and participation in follow-up program
  • Patient has previous history of infection in the affected joint and/or a local or systemic infection that may affect the prosthetic joint
  • Patient with mental or neurologic conditions who are unwilling or incapable of following postoperative care instructions
  • Patient with skeletal immaturity
  • Patient has insufficient bone stock on femoral or tibial surfaces
  • Patient with Neuropathic Arthropathy
  • Patient has osteoporosis, or any loss of musculature or neuromuscular disease that compromises the affected limb
  • Patient has severe instability secondary to the absence of collateral ligament integrity.
  • Patient has a stable, painless arthrodesis in a satisfactory functional position
  • Patient has rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin
  • Patient has a known or suspected sensitivity to one or more of the implant materials
  • Patient is undergoing procedures or treatments using ionizing radiation
  • Patients with known symptomatic foot, hip, or spinal injuries and/or conditions that could affect gait

Treatment and study plan

Total knee arthroplasty

Device

The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.

Primary outcomes

  1. Safety - Adverse Events

    Time frame: 5 years post TKA

    The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.

Secondary outcomes

  1. Percent of days with step-count data transmitted

    Time frame: 5 years post TKA

    Successful Data Collection

  2. Percent of days with one or more gait bouts triggered and transmitted

    Time frame: 5 years post TKA

    Successful Data Collection

  3. Percent of days with qualified gait cycles >0 (applicable for walking speed meter/second, stride length meter, tibia ROM, functional knee ROM and cadence)

    Time frame: 5 years post TKA

    Successful Data Collection

  4. Percent of days with step-count data transmitted and qualified gait cycles >0 (applicable for distance in meters)

    Time frame: 5 years post TKA

    Successful Data Collection

  5. Knee Injury and Osteoarthritis Outcome Score (KOOS - JR)

    Time frame: 5 years post TKA

    Pain and Functional Performance

  6. Numeric Pain Rating Scale (NPRS)

    Time frame: 5 years post TKA

    Pain and Functional Performance

  7. Quality-of-life- EQ-5D-5L

    Time frame: 5 years post TKA

    Pain and Functional Performance

Study contacts

Contact information is provided by the study sponsor or research team.

Anne Maurer, BS

CONTACT

[email protected]

Nora C.R. York, BS

CONTACT

[email protected]

7604976115

Sponsors and collaborators

Lead sponsor

Canary Medical

Industry

Collaborators

  • NAMSA

Registry information

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Sep 18, 2023
Registry last updated
Feb 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.